Research & Development

Developing the leading the treatment of adenoviral conjunctivitis

We are a clinical stage ophthalmic specialty biotechnology company.

We are exclusively focused on developing the leading treatment of adenoviral conjunctivitis (also known as pink eye).

Our lead product candidate, OKG-0502, is a topical, eye drop formulation of an anti-viral medication with an ocular decongestant.

Dig Deeper into our Research & Development

Adenoviral Conjunctivitis

Information About this Condition

RUBY Trial

Our Lead Clinical Program

Latest News & Press

View All News

Press Release

Okogen, Inc., Announces Ophthalmology Industry Veteran Joshua Moriarty as New Chief Executive Officer

March 8, 2022

Press Release

Safe, Effective and Dose Responsive Anti-Viral Activity of OKG-0301 in Patients with Acute Adenoviral Conjunctivitis–Phase 2 Interim Analysis Results from RUBY Clinical Trial

April 29, 2021

Press Release

Okogen Initiates Phase 2 Clinical Trial (RUBY) of OKG-0301 in Patients

January 31, 2019

© 2021 Okogen, Inc. All Rights Reserved

United States

Okogen, Inc.
332 Encinitas Blvd. Suite 102
Encinitas, CA 92024, USA

Australia

Okogen Pty Ltd
Level 9, 31 Queen St
Melbourne, VIC 3000 AUS